Merck has unveiled plans to invest €250 million in a new facility in Corsier-sur-Vevey, Switzerland. The new Merck Biotech Development Center will be dedicated to biotech development and manufacturing for clinical studies. Driven by the growth of the healthcare business sector R&D pipeline, the company says this investment will help to sustainably secure capacity and high agility to deliver clinical trial material in a cost-effective way, contribute to accelerated development timelines of new biological entities, and address the increasing manufacturing complexity of the next generations of biotech compounds.
 
“This investment in the Merck Biotech Development Center reflects our commitment to speed up the availability of new medicines for patients in need, and confirms the importance of Switzerland as our prime hub for the manufacturing of biotech medicines,” said Stefan Oschmann, chief executive officer, Merck.
 
Located near Merck’s current biotech commercial manufacturing site in Corsier-sur-Vevey, Switzerland, the Biotech Development Center will bridge together research and manufacturing. The facility will consist of a building providing a total of 15,700 square meters of development space bringing together a cross-functional team of approximately 250 employees spread across different sites today, responsible for advancing Merck’s biotech R&D pipeline by ensuring that Merck’s next generation of biotech therapies are available for clinical trials on time, on quality and on quantity.
 
Equipped with the most advanced digital solutions and highest technological standards, including continuous manufacturing and laboratory automation, the Biotech Development Center will offer a flexible-by-design infrastructure to readily adapt to emerging needs and technology evolution, as well as open workspaces enabling collaboration, creativity and innovation.
 
The Biotech Development Center will showcase Merck’s science and technology across its three business sectors, including Life Sciences’ process solutions for clinical manufacturing and pilot plant operations. The construction of the building is expected to be completed in 2021 and the Biotech Development Center is anticipated to be fully operational by the end of 2022 following validation by regulatory authorities.